Peggs KS - Search Results

1

Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.

Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T, Rosenthal R, Peacock T, Ronel T, Noursadeghi M, Turati V, Furness AJS, Georgiou A, Wong YNS, Ben Aissa A, Sunderland MW, Jamal-Hanjani M, Veeriah S, Birkbak NJ, Wilson GA, Hiley CT, Ghorani E, Guerra-Assunção JA, Herrero J, Enver T, Hadrup SR, Hackshaw A, Peggs KS, McGranahan N, Swanton C; TRACERx consortium; Quezada SA, Chain B. Joshi K, et al. Among authors: peggs ks. Nat Med. 2019 Oct;25(10):1549-1559. doi: 10.1038/s41591-019-0592-2. Epub 2019 Oct 7. Nat Med. 2019. PMID: 31591606 Free PMC article.

2

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.

Peggs KS, Quezada SA, Korman AJ, Allison JP. Peggs KS, et al. Curr Opin Immunol. 2006 Apr;18(2):206-13. doi: 10.1016/j.coi.2006.01.011. Epub 2006 Feb 7. Curr Opin Immunol. 2006. PMID: 16464564 Review.

3

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

Quezada SA, Peggs KS, Curran MA, Allison JP. Quezada SA, et al. Among authors: peggs ks. J Clin Invest. 2006 Jul;116(7):1935-45. doi: 10.1172/JCI27745. Epub 2006 Jun 15. J Clin Invest. 2006. PMID: 16778987 Free PMC article.

4

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.

Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Quezada SA, et al. Among authors: peggs ks. J Exp Med. 2008 Sep 1;205(9):2125-38. doi: 10.1084/jem.20080099. Epub 2008 Aug 25. J Exp Med. 2008. PMID: 18725522 Free PMC article.

5

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.

Peggs KS, Quezada SA, Allison JP. Peggs KS, et al. Immunol Rev. 2008 Aug;224:141-65. doi: 10.1111/j.1600-065X.2008.00649.x. Immunol Rev. 2008. PMID: 18759925 Review.

6

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.

Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Peggs KS, et al. J Exp Med. 2009 Aug 3;206(8):1717-25. doi: 10.1084/jem.20082492. Epub 2009 Jul 6. J Exp Med. 2009. PMID: 19581407 Free PMC article.

7

Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.

Peggs KS, Quezada SA, Allison JP. Peggs KS, et al. Clin Exp Immunol. 2009 Jul;157(1):9-19. doi: 10.1111/j.1365-2249.2009.03912.x. Epub 2009 Feb 18. Clin Exp Immunol. 2009. PMID: 19659765 Free PMC article. Review.

8

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.

Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP. Quezada SA, et al. Among authors: peggs ks. J Exp Med. 2010 Mar 15;207(3):637-50. doi: 10.1084/jem.20091918. Epub 2010 Feb 15. J Exp Med. 2010. PMID: 20156971 Free PMC article.

9

Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma.

Peggs KS, Quezada SA. Peggs KS, et al. Expert Rev Anticancer Ther. 2010 Nov;10(11):1697-701. doi: 10.1586/era.10.144. Expert Rev Anticancer Ther. 2010. PMID: 21080797 Review.

10

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.

Quezada SA, Peggs KS, Simpson TR, Allison JP. Quezada SA, et al. Among authors: peggs ks. Immunol Rev. 2011 May;241(1):104-18. doi: 10.1111/j.1600-065X.2011.01007.x. Immunol Rev. 2011. PMID: 21488893 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

187 results

Search Page